MONTREAL, CANADA -- (MARKET WIRE) -- May 24, 2007 -- ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that the preliminary clinical results from its breast cancer treatment monitoring pilot study conducted at the Sunnybrook Health Sciences Centre using its SoftScan® optical imaging device were positive. “Preliminary results are in line with expectations, suggesting that our SoftScan optical imaging device will be effective at showing early tumor response to breast cancer treatment,” said Sebastien Gignac, President and CEO of ART. “Using SoftScan as a monitoring tool, oncologists will see early on if a course of action is ineffective and then be able to adjust or interrupt treatment to pursue other alternatives. This will lead to shorter treatments, less suffering, and better results for the patient”, added Mr. Gignac. The preliminary results of the study will be presented at the Company’s annual meeting of shareholders in Montreal that is scheduled for May 25, 2007.
